Effect of Remogliflozin Compared To Empagliflozin in T2D patients With Chronic Heart Failure
A multicentric, prospective study showed that remogliflozin improved glycaemic parameters and NTproBNP in type 2 diabetes patients with Chronic Heart Failure (EF < 40%) in 3 months. Systolic BP reduced from 127±21 mmHg at baseline to 123±14 mmHg at 3 months in R group (p < 0.05). Remogliflozin was well tolerated and non-inferior to Empagliflozin in the patients.
Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial
Participants with lymphoma who were treated with anthracyclines, the prophylactic use of Atorvastatin over 12 months was associated with a lower rate of cardiac systolic dysfunction. At baseline, the LVEF was 63±4.6%. At 12 months, the LVEF was 59±5.9%. 46 participants (15%) had a decline in the LVEF of ≥ 10%. Adherence with study drug was documented in > 90%.
Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation
TriClip therapy reduces tricuspid regurgitation in 87% patients, and reduction is sustained to 1- year follow-up. The degree of TR reduction is related to the degree of improvement in QOL. The 30-day MAE rate was only 1.7%, and death and pacemaker implant each occurred in 0.6%. Survival free of mortality and TV surgery are high at 1 year (~90%).
Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients
The CLEAR OUTCOMES trial showed that bempedoic acid is well tolerated and reduces major adverse cardiovascular outcomes in patients intolerant to statins. It lowers LDL C by 21.7% and hsCRP by 22.2% with small increases in the incidence of gout and cholelithiasis. 4 component MACE are reduced by 13%, 3 component MACE by15%, myocardial infarction by 23% and coronary revascularization by 19%.
